A double miss on earnings and revenue barely matters next to the FDA decision on Galleri expected by early Q1 2027, which would open the door to broad reimbursement. Galleri screening revenue still grew 14% in the meantime.
Latest Activity
GRAL Coverage
Her Doctor Will Order a $949 Blood Test That Screens for Multiple Cancers. Medicare Will Pay $0 Toward the Test, Leaving Her With the Entire Bill Before Any Coverage Decision in 2029
Congress finally cleared a path for Medicare to cover a multi-cancer blood test, but a quirk in the fine print moves the goalposts every year. For one 70-year-old patient, the clock may…
Why CVS Is ‘Insanely Cheap,’ ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether…
Here Are Thursday’s Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More
Pre-Market Stock Futures: Futures are trading lower on Thursday, as Walmart’s forward outlook was disappointing. Risk-on was back on Wednesday, as the stock market, which is off to its worst start of…
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AT&T, Beyond Meat, Carvana, Fortinet, Snowflake, Waste Managment and More
Pre-Market Stock Futures: The futures are trading higher as we reach the midpoint of the trading week. The Dow Jones Industrial Average posted a stellar day on Tuesday, rising 1.20% to close…